vs
徕博科（LH）与Raymond James Financial（RJF）财务数据对比。点击上方公司名可切换其他公司
Raymond James Financial的季度营收约是徕博科的1.2倍（$4.2B vs $3.5B），Raymond James Financial净利率更高（13.5% vs 4.7%，领先8.8%），徕博科同比增速更快（5.6% vs 3.5%），徕博科自由现金流更多（$490.3M vs $-56.0M），过去两年Raymond James Financial的营收复合增速更高（7.1% vs 5.2%）
徕博科（Labcorp）是全球领先的生命科学与诊断检测企业，面向医疗机构、制药企业和个人患者提供全面的临床检验服务、药物研发支持及医疗检测解决方案，依托先进科研经验与创新技术输出准确可落地的健康洞察，助力临床决策、加快新药研发，提升全球患者健康水平。
雷蒙德詹姆斯金融是美国跨国独立投资银行及金融服务机构，通过旗下子公司为个人、企业及市政主体提供多元金融服务，核心业务覆盖投资与财务规划、投资银行、资产管理等领域，总部位于美国佛罗里达州圣彼得堡。
LH vs RJF — 直观对比
营收规模更大
RJF
是对方的1.2倍
$3.5B
营收增速更快
LH
高出2.1%
3.5%
净利率更高
RJF
高出8.8%
4.7%
自由现金流更多
LH
多$546.3M
$-56.0M
两年增速更快
RJF
近两年复合增速
5.2%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $3.5B | $4.2B |
| 净利润 | $164.7M | $563.0M |
| 毛利率 | 28.2% | — |
| 营业利润率 | 7.6% | — |
| 净利率 | 4.7% | 13.5% |
| 营收同比 | 5.6% | 3.5% |
| 净利润同比 | 14.9% | -6.2% |
| 每股收益（稀释后） | $1.98 | $2.79 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收LHRJF
| Q4 25 | $3.5B | $4.2B | ||
| Q3 25 | $3.6B | $4.2B | ||
| Q2 25 | $3.5B | $3.8B | ||
| Q1 25 | $3.3B | $3.8B | ||
| Q4 24 | $3.3B | $4.0B | ||
| Q3 24 | $3.3B | $4.0B | ||
| Q2 24 | $3.2B | $3.8B | ||
| Q1 24 | $3.2B | $3.6B |
净利润LHRJF
| Q4 25 | $164.7M | $563.0M | ||
| Q3 25 | $261.1M | $604.0M | ||
| Q2 25 | $237.9M | $436.0M | ||
| Q1 25 | $212.8M | $495.0M | ||
| Q4 24 | $143.4M | $600.0M | ||
| Q3 24 | $169.3M | $602.0M | ||
| Q2 24 | $205.3M | $492.0M | ||
| Q1 24 | $228.0M | $476.0M |
毛利率LHRJF
| Q4 25 | 28.2% | — | ||
| Q3 25 | 28.8% | — | ||
| Q2 25 | 29.7% | — | ||
| Q1 25 | 28.3% | — | ||
| Q4 24 | 26.9% | — | ||
| Q3 24 | 27.6% | — | ||
| Q2 24 | 28.8% | — | ||
| Q1 24 | 28.2% | — |
营业利润率LHRJF
| Q4 25 | 7.6% | — | ||
| Q3 25 | 11.1% | — | ||
| Q2 25 | 11.2% | 14.7% | ||
| Q1 25 | 9.7% | 17.5% | ||
| Q4 24 | 6.5% | 18.6% | ||
| Q3 24 | 7.7% | — | ||
| Q2 24 | 9.2% | 17.1% | ||
| Q1 24 | 10.1% | 16.7% |
净利率LHRJF
| Q4 25 | 4.7% | 13.5% | ||
| Q3 25 | 7.3% | 14.4% | ||
| Q2 25 | 6.7% | 11.3% | ||
| Q1 25 | 6.4% | 12.9% | ||
| Q4 24 | 4.3% | 14.9% | ||
| Q3 24 | 5.2% | 15.0% | ||
| Q2 24 | 6.4% | 13.1% | ||
| Q1 24 | 7.2% | 13.1% |
每股收益（稀释后）LHRJF
| Q4 25 | $1.98 | $2.79 | ||
| Q3 25 | $3.12 | $2.96 | ||
| Q2 25 | $2.84 | $2.12 | ||
| Q1 25 | $2.52 | $2.36 | ||
| Q4 24 | $1.72 | $2.86 | ||
| Q3 24 | $2.00 | $2.85 | ||
| Q2 24 | $2.43 | $2.31 | ||
| Q1 24 | $2.69 | $2.22 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $532.3M | $9.9B |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $8.6B | $12.6B |
| 总资产 | $18.4B | $88.8B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资LHRJF
| Q4 25 | $532.3M | $9.9B | ||
| Q3 25 | $598.1M | $11.4B | ||
| Q2 25 | $647.3M | $9.2B | ||
| Q1 25 | $369.4M | $9.7B | ||
| Q4 24 | $1.5B | $10.0B | ||
| Q3 24 | $1.5B | $11.0B | ||
| Q2 24 | $265.1M | $9.1B | ||
| Q1 24 | $99.3M | $10.0B |
股东权益LHRJF
| Q4 25 | $8.6B | $12.6B | ||
| Q3 25 | $8.7B | $12.5B | ||
| Q2 25 | $8.5B | $12.3B | ||
| Q1 25 | $8.3B | $12.2B | ||
| Q4 24 | $8.1B | $11.9B | ||
| Q3 24 | $8.2B | $11.7B | ||
| Q2 24 | $8.0B | $11.2B | ||
| Q1 24 | $8.0B | $11.0B |
总资产LHRJF
| Q4 25 | $18.4B | $88.8B | ||
| Q3 25 | $18.3B | $88.2B | ||
| Q2 25 | $18.1B | $84.8B | ||
| Q1 25 | $17.6B | $83.1B | ||
| Q4 24 | $18.4B | $82.3B | ||
| Q3 24 | $18.6B | $83.0B | ||
| Q2 24 | $16.7B | $80.6B | ||
| Q1 24 | $16.5B | $81.2B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $614.2M | $-10.0M |
| 自由现金流经营现金流 - 资本支出 | $490.3M | $-56.0M |
| 自由现金流率自由现金流/营收 | 13.9% | -1.3% |
| 资本支出强度资本支出/营收 | 3.5% | 1.1% |
| 现金转化率经营现金流/净利润 | 3.73× | -0.02× |
| 过去12个月自由现金流最近4个季度 | $1.2B | $1.4B |
8季度趋势，按日历期对齐
经营现金流LHRJF
| Q4 25 | $614.2M | $-10.0M | ||
| Q3 25 | $387.2M | $796.0M | ||
| Q2 25 | $620.6M | $691.0M | ||
| Q1 25 | $18.5M | $117.0M | ||
| Q4 24 | $777.2M | $830.0M | ||
| Q3 24 | $277.3M | $510.0M | ||
| Q2 24 | $561.1M | $711.0M | ||
| Q1 24 | $-29.8M | $391.0M |
自由现金流LHRJF
| Q4 25 | $490.3M | $-56.0M | ||
| Q3 25 | $280.5M | $752.0M | ||
| Q2 25 | $542.7M | $634.0M | ||
| Q1 25 | $-107.5M | $71.0M | ||
| Q4 24 | $665.1M | $789.0M | ||
| Q3 24 | $161.5M | $460.0M | ||
| Q2 24 | $432.9M | $655.0M | ||
| Q1 24 | $-163.6M | $342.0M |
自由现金流率LHRJF
| Q4 25 | 13.9% | -1.3% | ||
| Q3 25 | 7.9% | 17.9% | ||
| Q2 25 | 15.4% | 16.5% | ||
| Q1 25 | -3.2% | 1.8% | ||
| Q4 24 | 20.0% | 19.6% | ||
| Q3 24 | 4.9% | 11.5% | ||
| Q2 24 | 13.4% | 17.4% | ||
| Q1 24 | -5.2% | 9.4% |
资本支出强度LHRJF
| Q4 25 | 3.5% | 1.1% | ||
| Q3 25 | 3.0% | 1.1% | ||
| Q2 25 | 2.2% | 1.5% | ||
| Q1 25 | 3.8% | 1.2% | ||
| Q4 24 | 3.4% | 1.0% | ||
| Q3 24 | 3.5% | 1.2% | ||
| Q2 24 | 4.0% | 1.5% | ||
| Q1 24 | 4.2% | 1.3% |
现金转化率LHRJF
| Q4 25 | 3.73× | -0.02× | ||
| Q3 25 | 1.48× | 1.32× | ||
| Q2 25 | 2.61× | 1.58× | ||
| Q1 25 | 0.09× | 0.24× | ||
| Q4 24 | 5.42× | 1.38× | ||
| Q3 24 | 1.64× | 0.85× | ||
| Q2 24 | 2.73× | 1.45× | ||
| Q1 24 | -0.13× | 0.82× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
LH
| Diagnostics | $2.7B | 78% |
| Biopharma Laboratory Services | $793.0M | 23% |
RJF
暂无分部数据
